CalciMedica, Inc. (NASDAQ:CALC) Sees Significant Growth in Short Interest

CalciMedica, Inc. (NASDAQ:CALC) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 65,600 shares, an increase of 45.1% from the November 30th total of 45,200 shares. Currently, 0.9% of the shares of the stock are sold short. Based on an average trading volume of 57,700 shares, the short-interest ratio is currently 1.1 days.

Insiders Place Their Bets

In other CalciMedica news, insider Eric W. Roberts purchased 53,333 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was acquired at an average cost of $3.75 per share, with a total value of $199,998.75. Following the completion of the purchase, the insider now directly owns 164,706 shares in the company, valued at approximately $617,647.50. This represents a 47.89 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Fred A. Middleton purchased 87,744 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was bought at an average cost of $3.75 per share, for a total transaction of $329,040.00. Following the purchase, the director now owns 814,300 shares in the company, valued at $3,053,625. This trade represents a 12.08 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 252,744 shares of company stock valued at $942,510. Insiders own 41.55% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CALC. Atria Investments Inc increased its stake in CalciMedica by 136.5% during the 3rd quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock worth $117,000 after acquiring an additional 15,296 shares during the period. PVG Asset Management Corp acquired a new position in CalciMedica in the third quarter valued at about $67,000. Finally, Geode Capital Management LLC lifted its position in CalciMedica by 51.2% during the third quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock worth $295,000 after purchasing an additional 22,525 shares during the period.

CalciMedica Stock Down 3.2 %

Shares of CALC traded down $0.09 during midday trading on Monday, reaching $2.76. 5,505 shares of the stock were exchanged, compared to its average volume of 39,091. CalciMedica has a twelve month low of $2.05 and a twelve month high of $8.38. The stock’s 50 day simple moving average is $3.33 and its 200 day simple moving average is $4.02. The company has a market cap of $37.21 million, a P/E ratio of -2.56 and a beta of 1.25.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of CalciMedica in a research note on Thursday, November 14th.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.